Total Payments
$2,537
2024 Payments
$2,537
Companies
3
Transactions
11

Payment Breakdown by Category

Research$2,494 (98.3%)
Food & Beverage$42.70 (1.7%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2,494 9 98.3%
Food and Beverage $42.70 2 1.7%

Payments by Type

Research
$2,494
9 transactions
General
$42.70
2 transactions

Top Paying Companies

Company Total Records Latest Year
SANOFI US SERVICES INC. $2,494 9 $0 (2024)
Amgen Inc. $24.66 1 $0 (2024)
Incyte Corporation $18.04 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $2,537 11 SANOFI US SERVICES INC. ($2,494)

All Payment Transactions

11 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/14/2024 Incyte Corporation OPZELURA (Drug) Food and Beverage Cash or cash equivalent $18.04 General
Category: Dermatology
10/28/2024 Amgen Inc. Otezla (Drug) Food and Beverage In-kind items and services $24.66 General
Category: Inflammation
05/07/2024 SANOFI US SERVICES INC. Cash or cash equivalent $216.51 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/27/2024 SANOFI US SERVICES INC. In-kind items and services $1,190.11 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/27/2024 SANOFI US SERVICES INC. In-kind items and services $517.54 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/27/2024 SANOFI US SERVICES INC. In-kind items and services $247.28 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/26/2024 SANOFI US SERVICES INC. In-kind items and services $75.08 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/26/2024 SANOFI US SERVICES INC. In-kind items and services $50.21 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/26/2024 SANOFI US SERVICES INC. In-kind items and services $25.00 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/26/2024 SANOFI US SERVICES INC. In-kind items and services $25.00 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD
04/25/2024 SANOFI US SERVICES INC. In-kind items and services $147.40 Research
Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD

Research Studies & Clinical Trials

Study Name Company Amount Records
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD SANOFI US SERVICES INC. $2,494 9

About Mark Taliercio

Mark Taliercio is a Student in an Organized Health Care Education/Training Program healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2022. The National Provider Identifier (NPI) number assigned to this provider is 1902556145.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Taliercio has received a total of $2,537 in payments from pharmaceutical and medical device companies, with $2,537 received in 2024. These payments were reported across 11 transactions from 3 companies. The most common payment nature is "" ($2,494).

Practice Information

Products in Payments

  • Otezla (Drug) $24.66
  • OPZELURA (Drug) $18.04

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Albany